Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Introduction
Inhibitors Measured
Byproducts Measured
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 4: The Cholinergic Toxidrome
Section 10: Laboratory Assessment of the Cholinergic Toxidrome
Direct Measurement of Cholinesterase Inhibitors and Their Metabolic Byproducts


Learning Objectives

Upon completion of this section, you should be able to

  • Describe the usefulness of laboratory analysis for the presence of cholinesterase inhibitors themselves and their breakdown products in biological specimens.
  • Describe the limitations of laboratory analysis for the presence of cholinesterase inhibitors themselves and their breakdown products in biological specimens.

Introduction

While direct measurements of the actual cholinesterase inhibitors and their metabolic byproducts in body fluids are very accurate, (Clark 2002) their usefulness is limited because

  • Each test can only measure one chemical, so it is not useful if you do not know to which one the patient was exposed. (Schenker, Louie et al. 1998)
  • The results are not available in time to assist in critical treatment decisions. (Mortensen 1986; Schenker, Louie et al. 1998; Clark 2002)
  • Toxic levels for individual agents have not been established. (Erdman 2004)

However, when these test results are available, they can sometimes help in

  • Assessing public health exposure risks to others.
  • Providing forensic documentation of poisoning. (Wiener and Hoffman 2004)
  • Documenting exposures as a cause of disability.

Note: if such tests are needed, state or federal public laboratories can be consulted.


Cholinesterase Inhibitors That Can Be Measured

Listed below are some of the cholinesterase inhibitors that can be measured in biological fluids.

  • Sarin. (Abu-Qare and Abou-Donia 2002; Wiener and Hoffman 2004)
  • Some organophosphorus pesticides.
  • VX. (Wiener and Hoffman 2004)

Metabolic Byproducts That Can Be Measured

Alkyl phosphate and phenols (e.g., paranitrophenol (Durham and Hayes 1962)), which are byproducts of organophosphorus compounds

  • Are sometimes used to quantitate exposure. (Mortensen 1986)
  • Do not correlate with cholinesterase levels. (Namba 1971)
  • May be detected for up to 48 hours in urine.
  • May be positive before clinical signs appear or cholinesterase levels decrease). (Reigart and Roberts 1999)

Note: Excretion of OP compounds and metabolites is rapid while cholinesterase levels remain depressed for a longer period. (Karalliedde and Senanayake 1989)


Key Points

  • While direct measurement of cholinesterase inhibitors or their metabolic byproducts is very accurate, results are not generally available in time to guide acute treatment decisions.
  • They can sometimes be helpful, however, for forensic and public health purposes.

Progress Check

30. Which of the following are true about direct laboratory measurement of cholinesterase inhibitors and their byproducts? (Choose ALL correct answers)

A. Unlike cholinesterase measurements, they are rapidly available to most hospital emergency departments.
B. They are only useful, if you know what chemical you are looking for.
C. Toxic levels for individual agents have not been established.
D. They may be useful for forensic documentation of exposure.
E. None of the above.

Answer:

To review relevant content, see Introduction in this section.


Previous Section

Next Section

Revised 2007-10-16.